BACKGROUND Heart failure after an acute myocardial infarction (AMI) is a major cause of morbidity and mortality
A cute myocardial infarction (AMI) due to occlusion of a coronary artery is a major cause of global morbidity and mortality (1) . The current paradigm for AMI therapy focuses on rapidly restoring coronary artery blood flow to re-establish myocardial oxygen supply, known as primary reperfusion (P-reperfusion). However, despite timely reperfusion, up to 25% of patients experiencing their first AMI will develop heart failure within 1 year (2) . For every 5% increase in myocardial infarct size, 1-year all-cause mortality and heart failure hospitalizations increase by 20%, which imposes a significant burden on health care resources (3) . For these reasons, new approaches to limit myocardial damage and subsequent ischemic heart failure remain a significant unmet need for patients with AMI.
One explanation for these poor outcomes is that P-reperfusion paradoxically worsens myocardial damage, known as ischemiareperfusion injury. Prior attempts to limit ischemia-reperfusion injury via vascular conditioning approaches to activate reperfusion injury salvage kinase (RISK) pathway activity or pharmacological approaches have failed to show clear clinical benefit (4, 5) .
A critical barrier to these cardioprotective strategies is the mandate for rapid coronary reperfusion and therefore insufficient time for any therapeutic impact on myocardial injury. Improved strategies are needed to limit myocardial damage by promoting cardioprotective mechanisms before reperfusion of an infarct-related artery.
Over the past decade, percutaneously delivered transvalvular axial-flow pumps (TV-pumps) have been introduced into routine clinical practice. These devices rapidly reduce left ventricular (LV) wall stress, stroke work, and myocardial oxygen demand, while augmenting systemic mean arterial pressure without the need for surgery (6) (7) (8) . We recently reported that compared with P-reperfusion, first unloading the left ventricle by using a TV-pump while delaying coronary reperfusion (primary unloading [P-unloading]) reduced myocardial infarct size by 40% to 50% (9) .
We further identified that P-unloading increases myocardial levels and activity of stromal-derived factor (SDF)-1a (CXCL-12), which is a constitutively and ubiquitously expressed cytokine that promotes cardioprotective signaling in AMI (10) . The mechanism by which P-unloading regulates SDF-1a levels remains unknown.
In the setting of myocardial ischemia-reperfusion injury, increased expression of proteases, including matrix metalloprotease (MMP)-2 and MMP-9 and dipeptidyl peptidase-4 (DPP-4), cleave the N-terminus of SDF-1a, thereby rendering the cytokine inactive (11) (12) (13) (14) . Any remaining SDF-1a can bind to CXCR4, which promotes phosphorylation of the RISK pathway including extracellular regulated kinase (Erk), protein kinase b (Akt), and glycogen synthase kinase 3b (GSK3b). RISK activation promotes cell survival by limiting cardiomyocyte apoptosis and maintains mitochondrial integrity by preventing opening of the mitochondrial trans-permeability pore (15) (16) (17) .
The mechanisms underlying the cardioprotective benefit of P-unloading and whether the acute decrease in infarct size results in a durable reduction in LV scar and improvement in cardiac function remain unknown. The present study tested the importance of delayed myocardial reperfusion, explored cardioprotective mechanisms, and determined the late-term impact on myocardial function associated with P-unloading. In total, 7 (37%) of 19 animals died during the study protocol. The surviving 12 animals were used for analysis in the chronic study, in either the P-reperfusion group (n ¼ 6), or the P-unloading group (n ¼ 6) ( Figure 1A were measured at 28 days after the initial infarct in the chronic-phase study by using a solid-state pressure transducer and dual-field excitation mode, respectively, as previously described (18, 19) . Briefly, the and -dP/dtmin. LV stroke work was calculated as the product of peak LV peak systolic pressure and stroke volume.
DETERMINATION OF MYOCARDIAL INFARCT SIZE.
Upon completion of the acute study protocol, balloon occlusion was performed within the mid-LAD stent and Evans blue injected into both coronary vessels to delineate the area-at-risk followed by removal and sectioning of the left ventricle. Biopsy specimens were obtained from the antero-apical left ventricle distal to the site of stent deployment (infarct zone) and from the postero-basal wall (noninfarct zone) for molecular analysis; LV slices were then incubated in 1% triphenyltetrazolium chloride, as previously described. To quantify LV scar size 28 days after MI, the left ventricle was sectioned into five 1-cm slices and then incubated in triphenyltetrazolium chloride without Evans blue. LV slices were then photographed, and 3 blinded reviewers used digitized planimetry to quantify the total myocardial area, area-at-risk, and infarct zone.
CARDIAC MRI WITH LATE-GADOLINIUM ENHANCEMENT.
Animals in the chronic-phase study underwent a cardiac MRI with late-gadolinium enhancement (LGE) 28 days after the initial infarct using a Philips Achieva Total protein was extracted from tissue homogenates, isolated as previously described (22) (23) (24) . SDF-1a protein levels were quantified in LV tissue isolated from sham-operated animals and infarct zones using LEVELS AND ACTIVITY. MMP-2 and MMP-9 activities in homogenates of heart tissues were determined by zymography as previously described (25) . Briefly, gelatin zymography was performed with sodium dodecyl sulfate polyacrylamide gel electrophoresis gels containing 1 mg/ml of porcine gelatin. Samples were prepared under nonreducing conditions. Gel electrophoresis was performed at 150 V for 1 h.
After electrophoresis, the gel was washed in 2.5%
Triton X-100 solution with gentle agitation for 6 h at Expression of apoptosis regulatory protein levels were normalized to both total protein levels and glyceraldehyde-3-phosphate dehydrogenase. Table 1 ). Consistent with these observations, real-time PCR of LV tissue samples from the infarct zone confirmed that compared with group 1, group 3 exhibited increased messenger ribonucleic acid (mRNA) levels of key genes associated with cellular respiration ( Figure 2B ). Electron microscopy further showed loss of mitochondrial integrity within the infarct zone from group 1 (but not group 3) ( Figure 2C ). These findings identify that Compared with P-reperfusion, P-unloading reduced LV scar size quantified by using LGE (3.9 AE 3.2% vs. 9 AE 3.7%; p ¼ 0.03) and anatomic pathology (7.2 AE 4.9% vs. 14.9 AE 4.1%; p ¼ 0.02) ( Figure 5A ). Table 1) .
PRIMARY UNLOADING INCREASES CIRCULATING AND TISSUE LEVELS OF SDF-1a LEVELS ACUTELY
AND 28 DAYS AFTER AMI. Compared with P-reperfusion, P-unloading increased circulating SDF-1a levels during the 28 days after AMI with a peak SDF-1a level 1 week after AMI ( Figure 5E ). In contrast, P-reperfusion failed to increase circulating SDF-1a levels at any time point after AMI. Compared with sham controls, P-reperfusion decreased SDF-1a protein levels within the infarct zone of the left ventricle, but P-unloading did not. Circulating SDF-1a levels on day 28 after AMI correlated inversely with LV scar size ( Figures 5F and 5G ). (Impella) directly into the left ventricle and delaying coronary reperfusion for 60 min (9) . In both reports, infarct size was reduced by 40% to 50% despite delayed reperfusion and correlated with reduced LV wall stress and increased SDF-1a levels and activity.
Based on the population studies described here, if a fraction of the infarct reduction observed in these preclinical models is evident in humans, P-unloading could improve survival and reduce ischemic heart failure after AMI. In this report, we sought to address the following: 1) the importance of delayed reperfusion after LV unloading; 2) the impact of P-unloading on global myocardial gene expression; 3) the mechanism by which P-unloading increases SDF-1a levels;
and 4) whether P-unloading can affect late-term LV remodeling weeks after AMI. Whether the delay to reperfusion after mechanical LV unloading is required to limit infarct size remains poorly understood. To address this question, we Mechanically unloading the left ventricle for a minimum of 30 min before reperfusion limits expression of proteolytic enzymes that degrade stromal-derived factor-1a (SDF1a), thereby increasing cardioprotective signaling improving cell survival, and reducing both acute infarct size and subsequent myocardial scar size 28 days after present study, we observed that compared with P-reperfusion, P-unloading failed to increase SDF-1a mRNA levels within the infarct zone. However, we did observe that compared with sham controls, Preperfusion reduced SDF-1a protein levels within the infarct zone. In contrast, LV unloading for 30 min before reperfusion preserved SDF-1a protein levels.
Because SDF-1a levels are highly regulated by proteases associated with inflammation, we next explored whether protein and activity levels of key regulatory proteases such as MMP-2, MMP-9, or DPP-4 were altered by P-reperfusion and P-unloading. Consistent with previous reports, we observed that compared with sham controls, P-reperfusion increases, but P-unloading attenuates, activity of these proteases. To further establish the downstream effect of P-unloading, we also observed reduced expression of proteins associated with apoptosis within the infarct zone. These findings suggest for the first time that 30 min of P-unloading limits protease activity within the infarct zone, which limits SDF-1a degradation in the setting of an AMI.
To better understand the potential for clinical translation of P-unloading, we designed a preclinical study in which animals were assigned to P-reperfusion or P-unloading and then quantified LV scar 28 days later by using cardiac MRI. We observed for the first time that P-unloading reduced infarct scar size as blindly quantified by LGE-CMR, which tightly correlated with anatomic measurements of myocardial scar size. We further quantified well-established molecular markers of maladaptive remodeling in the noninfarct zones where the bulk of compensatory remodeling would occur in response to a large anterior MI. We observed that compared with P-reperfusion, P-unloading reduced calcineurin, beta myosin heavy chain, and BNP levels, while preserving sarcoplasmic/endoplasmic reticulum calcium ATPase levels 28 days after AMI.
Furthermore, circulating and LV tissue levels of a clinically relevant biomarker of heart failure, BNP, were reduced after P-unloading but not after P-reperfusion. These findings are the first to identify that use of a transvalvular pump at the time of AMI has durable effects on both LV scar size and markers of maladaptive remodeling 28 days later.
For decades, we have focused on immediate reperfusion in AMI; however, these data suggest for the first time that the "pre-reperfusion time period" is a critical moment that may allow for interventions such as LV unloading and delayed reperfusion to have a durable effect on late-term cardiac remodeling. Whether these preclinical findings translate to clinical outcomes remain to be determined.
Finally, we quantified SDF-1a levels after AMI and observed increased circulating and LV tissue levels of SDF-1a levels 28 days after P-unloading but not after P-reperfusion. Circulating SDF-1a levels correlated inversely with LV scar size. These findings identify that in addition to providing an acute reduction in infarct size after MI, P-unloading promotes a more durable reduction in LV scar size, improves cardiac function, and limits maladaptive remodeling after AMI. By using clinically relevant biomarkers of myocardial injury, including CMR and circulating BNP levels, our findings suggest that there may be a strong translational potential for P-unloading as an approach to limit ischemic heart failure after AMI.
STUDY LIMITATIONS. Limitations include the small number of animals studied in the chronic phase, which was due in part to a 37% mortality rate among animals subjected to LAD occlusion and the cost associated with large-animal studies. Another limitation of this study is the duration of ischemia. All animals were subjected to 90 min of LAD occlusion.
However, duration of ischemia cannot be controlled for in the clinical setting. Future studies will further explore the functional role of SDF-1a in post-ischemic heart failure and the impact of P-unloading on other signaling pathways involving inflammation, fibrosis, and mitochondrial function. Future studies will also determine whether P-unloading can be combined with other cardioprotective approaches to incrementally reduce infarct size and to further study the lateterm effects of P-unloading months after acute MI. 
CONCLUSIONS

PERSPECTIVES COMPETENCY IN MEDICAL KNOWLEDGE:
Mechanically unloading the left ventricle for at least 30 min before coronary reperfusion increases signaling via the cardioprotective cytokine SDF-1a, and reduces infarct size and subsequent LV scarring.
TRANSLATIONAL OUTLOOK: Clinical studies are needed to assess the potential therapeutic value of primary unloading to prevent heart failure after AMI.
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